Differential pharmacodynamic effects of paclitaxel formulations in an intracranial rat brain tumor model

Journal of Pharmacology and Experimental Therapeutics

Volumn 332, Issue 2, 2010, Pages 479-488

  Zhou, Rong ^b,c   Mazurchuk, Richard V ^b   Tamburlin, Judith H ^a   Harrold, John M ^a   Mager, Donald E ^a   Straubinger, Robert M ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREMOPHOR; LIPOSOME; PACLITAXEL;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN CANCER; CANCER GROWTH; CANCER SIZE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; GLIOSARCOMA; LETHALITY; LIFESPAN; MALE; MAXIMUM TOLERATED DOSE; NANOPHARMACEUTICS; NEUROIMAGING; NEUTROPENIA; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIMARY TUMOR; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; TREATMENT RESPONSE; WEIGHT CHANGE; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BODY WEIGHT; BRAIN NEOPLASMS; CHEMISTRY, PHARMACEUTICAL; DISEASE MODELS, ANIMAL; DRUG SCREENING ASSAYS, ANTITUMOR; GLYCEROL; LIPOSOMES; MALE; MAXIMUM TOLERATED DOSE; MODELS, THEORETICAL; NEUTROPENIA; PACLITAXEL; RATS; RATS, INBRED STRAINS; TUMOR BURDEN; VEHICLES;

EID: 76749156155     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.160044     Document Type: Article

References (40)

1. Arnold RD, Mager DE, Slack JE, and Straubinger RM (2005) Effect of repetitive administration of doxorubicin-containing liposomes on plasma pharmacokinetics and drug biodistribution in a rat brain tumor model. Clin Cancer Res 11:8856-8865.
2. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, Giavazzi R, and Taraboletti G (1996) The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2:1843-1849.
3. Blagosklonny MV and Fojo T (1999) Molecular effects of paclitaxel: myths and reality (a critical review). Int J Cancer 83:151-156.
4. Bocci G, Nicolaou KC, and Kerbel RS (2002) Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 62:6938-6943.
5. Bulitta JB, Zhao P, Arnold RD, Kessler DR, Daifuku R, Pratt J, Luciano G, Hanauske AR, Gelderblom H, Awada A, et al. (2009a) Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients. Cancer Chemother Pharmacol 63:1049-1063.
6. Bulitta JB, Zhao P, Arnold RD, Kessler DR, Daifuku R, Pratt J, Luciano G, Hanauske AR, Gelderblom H, Awada A, et al. (2009b) Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients. Cancer Chemother Pharmacol 63:1035-1048.
7. Chang SM, Kuhn JG, Robins HI, Schold SC Jr, Spence AM, Berger MS, Mehta M, Pollack IF, Rankin C, and Prados MD (2001) A Phase II study of paclitaxel in patients with recurrent malignant glioma using different doses depending upon the concomitant use of anticonvulsants: a North American Brain Tumor Consortium report. Cancer 91:417-422.
8. Constantinides PP, Han J, and Davis SS (2006) Advances in the use of tocols as drug delivery vehicles. Pharmacol Res 23:243-255.
9. Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, Tao C, De T, Beals B, Dykes D, et al. (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12:1317-1324.
10. Drummond DC, Meyer O, Hong K, Kirpotin DB, and Papahadjopoulos D (1999) Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51:691-743.
11. Fetterly GJ, Grasela TH, Sherman JW, Dul JL, Grahn A, Lecomte D, Fiedler-Kelly J, Damjanov N, Fishman M, Kane MP, et al. (2008) Pharmacokinetic/ pharmacodynamic modeling and simulation of neutropenia during Phase I development of liposome entrapped paclitaxel. Clin Cancer Res 14:5856-5863.
12. Fetterly GJ and Straubinger RM (2003) Pharmacokinetics of paclitaxel-containing liposomes in rats. AAPS PharmSci 5:E32.
13. Fetterly GJ, Tamburlin JM, and Straubinger RM (2001) Paclitaxel pharmacodynamics: application of a mechanism-based neutropenia model. Biopharm Drug Dispos 22:251-261.
14. Gardner ER, Dahut WL, Scripture CD, Jones J, Aragon-Ching JB, Desai N, Hawkins MJ, Sparreboom A, and Figg WD (2008) Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res 14:4200-4205.
15. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, and O'Shaughnessy J (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23:7794-7803.
16. Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, Esmaeli B, Ring SE, Bedikian A, Hortobagyi GN, et al. (2002) Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8:1038-1044.
17. Jang SH, Wientjes MG, and Au JL (2001) Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: effect of treatment schedule. J Pharmacol Exp Ther 296:1035-1042.
18. Kadota T, Chikazawa H, Kondoh H, Ishikawa K, Kawano S, Kuroyanagi K, Hattori N, Sakakura K, Koizumi S, Hiraiwa E, et al. (1994) Toxicity studies of paclitaxel (I): single dose intravenous toxicity in rats. J Toxicol Sci 19 (Suppl 1):1-9.
19. Ling X, Bernacki RJ, Brattain MG, and Li F (2004) Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest. J Biol Chem 279:15196-15203.
20. Lobo ED and Balthasar JP (2002) Pharmacodynamic modeling of chemotherapeutic effects: application of a transit compartment model to characterize methotrexate effects in vitro. AAPS PharmSci 4:E42.
21. Lu D, Wientjes MG, Lu Z, and Au JL (2007) Tumor priming enhances delivery and efficacy of nanomedicines. J Pharmacol Exp Ther 322:80-88.
22. Mager DE and Jusko WJ (2001) Pharmacodynamic modeling of time-dependent transduction systems. Clin Pharmacol Ther 70:210-216.
23. Mayer LD, Hope MJ, and Cullis PR (1986) Vesicles of variable sizes produced by a rapid extrusion procedure. Biochim Biophys Acta 858:161-168.
24. Nyman DW, Campbell KJ, Hersh E, Long K, Richardson K, Trieu V, Desai N, Hawkins MJ, and Von Hoff DD (2005) Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol 23:7785-7793.
25. Pasquier E, Honore S, Pourroy B, Jordan MA, Lehmann M, Briand C, and Braguer D (2005) Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res 65:2433-2440.
26. Postma TJ, Heimans JJ, Luykx SA, van Groeningen CJ, Beenen LF, Hoekstra OS, Taphoorn MJ, Zonnenberg BA, Klein M, and Vermorken JB (2000) A phase II study of paclitaxel in chemonaive patients with recurrent high-grade glioma. Ann Oncol 11:409-413.
27. Riondel J, Jacrot M, Fessi H, Puisieux F, and Potier (1992) Effects of free and liposome-encapsulated taxol on two brain tumors xenografted into nude mice. In Vivo 6:23-27.
28. Sharma A, Mayhew E, and Straubinger RM (1993) Antitumor effect of taxol-containing liposomes in a taxol-resistant murine tumor model. Cancer Res 53: 5877-5881.
29. Sharma A and Straubinger RM (1994) Novel taxol formulations: preparation and characterization of taxol-containing liposomes. Pharm Res 11:889-896.
30. Sharma US, Sharma A, Chau RI, and Straubinger RM (1997) Liposome-mediated therapy of intracranial brain tumors in a rat model. Pharm Res 14:992-998.
31. Simeoni M, Magni P, Cammia C, De Nicolao G, Croci V, Pesenti E, Germani M, Poggesi I, and Rocchetti M (2004) Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res 64:1094-1101.
32. Sparreboom A, Baker SD, and Verweij J (2005a) Paclitaxel repackaged in an albumin-stabilized nanoparticle: handy or just a dandy? J Clin Oncol 23:7765-7767.
33. Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A, Beals B, Figg WD, Hawkins M, and Desai N (2005b) Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res 11:4136-4143.
34. Sun YN and Jusko WJ (1998) Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics. J Pharm Sci 87:732-737.
35. ten Tije AJ, Verweij J, Loos WJ, and Sparreboom A (2003) Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 42:665-685.
36. Trédan O, Galmarini CM, Patel K, and Tannock IF (2007) Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99:1441-1454.
37. Wang J, Lou P, Lesniewski R, and Henkin J (2003) Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs 14:13-19.
38. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker JR Jr, Van Echo DA, Von Hoff DD, and Leyland-Jones B (1990) Hypersensitivity reactions from taxol. J Clin Oncol 8:1263-1268.
39. Yang J, Mager DE and Straubinger RM (2009) Comparison of two pharmacodynamic transduction models for the analysis of tumor therapeutic responses in model systems. AAPS J doi: 10.1208/s12248-009-9155-7.
40. Zhou R, Mazurchuk R, and Straubinger RM (2002) Antivasculature effects of doxorubicin-containing liposomes in an intracranial rat brain tumor model. Cancer Res 62:2561-2566.